ViroPharma (VPHM) Could Draw 50% Premium in Takeover
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Equities close higher as softer jobs data quiets rate-hike expectations
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Deutsche Bank Cuts ViroPharma (VPHM) to Hold; Takeout Premium Reflected in Price
September 19, 2013 7:28 AM EDTDeutsche Bank downgraded ViroPharma (NASDAQ: VPHM) from Buy to Hold with a price target of $43.00 (from $38.00). Analyst Robyn Karnauskas thinks the stock's current price reflects most of the M&A takeout premium.
"Press sources on 9/13 (Bloomberg) stated that Viropharma has hired... More
UPDATE: ViroPharma Inc. (VPHM) Hires Goldman to Explore Sale - Bloomberg
September 13, 2013 1:00 PM EDT(Updated - September 13, 2013 1:08 PM EDT)
ViroPharma Inc. (Nasdaq: VPHM) has attracted takeover interest from Sanofi (NYSE: SNY) and Shire (NYSE: SHPG), according to Bloomberg sources. The company has hired Goldman Sachs to manage a potential auction, and the Bank has is seeking other bidders.... More
